Type 2 Diabetic Patients Clinical Trial
Official title:
Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Treatment of Patients With Newly Diagnosed Type 2 Diabetes: a Multicenter, Randomized Open Trial Study With Parallel Controls
The efficacy, safety and post-treatment disease control will be compared between treatments consisting of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.
Based on the dual roles of glucagon-like peptide 1 (GLP-1) in regulating fasting blood
glucose and postprandial blood glucose secretion, we adopted a combinational therapeutic
model and will administer drug treatments during basic meals. Newly diagnosed type 2 diabetic
patients will be administered continuous subcutaneous Beinaglutide injections using a pump
device. The efficacy, safety and disease control after terminating the drug treatments will
be compared to those of patients who receive CSII treatment.
This is a national-level, multicenter, randomized, open study with parallel controls. The
study consists of two phases:
a five-week treatment phase and a 48-week post-treatment follow-up period.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03006159 -
A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients
|
Phase 1 | |
| Completed |
NCT01049750 -
Prevalence and Risk Factors of Erectile Dysfunction in Type 2 Diabetic Patients
|
N/A | |
| Completed |
NCT01049321 -
The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients
|
Phase 4 | |
| Completed |
NCT02164578 -
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk
|
Phase 3 | |
| Completed |
NCT00941148 -
Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin
|
Phase 4 |